Deal Library / Pharma BD Deal Intelligence

GlaxoSmithKline plc — Pharma Deals

The Pharma Closeout tracks 25 deals, $54.9B in disclosed deal value, 19 with a post-close Outcome Score for GlaxoSmithKline plc.

Median Critic Score: 71 · Median Outcome Score: 37

Best outcome: GlaxoSmithKline plc / Theravance, Inc. (82) · Weakest outcome: GlaxoSmithKline plc / Sirtris Pharmaceuticals, Inc. (9)

All 25 deals

GlaxoSmithKline plc / Theravance, Inc. — 2012 · $213M · Worked — the deal delivered on its rationale.
GlaxoSmithKline plc / Tesaro Inc. — 2018 · $5.1B · Worked — the deal delivered on its rationale.
GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) — 2018 · $12.7B · Worked — the deal delivered on its rationale.
GlaxoSmithKline plc / Novartis Consumer Healthcare JV — 2018 · $13.0B · Largely worked — most objectives met.
GlaxoSmithKline plc / ID Biomedical Corporation — 2005 · $1.4B · Largely worked — most objectives met.
GlaxoSmithKline plc / Vir Biotechnology Inc. — 2020 · $595M · Mixed — partial payoff, real shortfalls.
GlaxoSmithKline plc / Reliant Pharmaceuticals Inc. — 2007 · $1.6B · Mixed — partial payoff, real shortfalls.
GlaxoSmithKline plc / GlaxoSmithKline Pharmaceuticals Limited (India) — minority stake increase — 2013 · $1.0B · Underwhelmed — fell short of the thesis.
GlaxoSmithKline plc / Domantis Limited — 2007 · $454M · Underwhelmed — fell short of the thesis.
GlaxoSmithKline plc / 23andMe, Inc. — 2018 · $300M · Underwhelmed — fell short of the thesis.
GlaxoSmithKline plc / Genmab A/S (ofatumumab/HuMax-CD20) — 2006 · $2.1B · Underwhelmed — fell short of the thesis.
GlaxoSmithKline plc / Genmab A/S (HuMax-TAC follow-on) — 2009 · $102M · Underwhelmed — fell short of the thesis.
GlaxoSmithKline plc / Merck KGaA — 2019 · $4.2B · Did not work — the deal failed to deliver.
GlaxoSmithKline plc / Stiefel Laboratories, Inc. — 2009 · $3.6B · Did not work — the deal failed to deliver.
GlaxoSmithKline plc / iTeos Therapeutics S.A. — 2021 · $2.1B · Did not work — the deal failed to deliver.
GlaxoSmithKline plc / Domantis Limited — 2006 · $454M · Did not work — the deal failed to deliver.
GlaxoSmithKline plc / Genelabs Technologies, Inc. — 2008 · $57M · Did not work — the deal failed to deliver.
GlaxoSmithKline plc / Laboratorios Phoenix — 2010 · $253M · Did not work — the deal failed to deliver.
GlaxoSmithKline plc / Sirtris Pharmaceuticals, Inc. — 2008 · $720M · Did not work — the deal failed to deliver.
GlaxoSmithKline plc / Frontier Biotechnologies Inc. — 2026 · $1.0B
GlaxoSmithKline plc / Vir Biotechnology Inc. — 2021 · $345M
GlaxoSmithKline plc / Alector, Inc. — 2021 · $2.2B
GlaxoSmithKline plc / CureVac N.V. — 2020 · $960M
GlaxoSmithKline plc / Adaptimmune Therapeutics plc — 2014 · $350M
GlaxoSmithKline plc / Concert Pharmaceuticals, Inc. — 2009 · $35M

← Deal Library · Interactive search · How we score deals